{"id":"amoxicillin-rifabutin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Uveitis (rifabutin-associated)"}]},"_chembl":{"chemblId":"CHEMBL444633","moleculeType":"Small molecule","molecularWeight":"847.02"},"_dailymed":{"setId":"68c4e9dc-dbcf-4151-b6f7-5e4b9922b76f","title":"TALICIA (OMEPRAZOLE MAGNESIUM, AMOXICILLIN AND RIFABUTIN) CAPSULE, DELAYED RELEASE [REDHILL BIOPHARMA LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin is a beta-lactam antibiotic that binds penicillin-binding proteins and disrupts peptidoglycan cross-linking in the bacterial cell wall, leading to cell lysis. Rifabutin is a rifamycin that binds bacterial RNA polymerase, blocking transcription and preventing bacterial protein synthesis. Together, they provide broad-spectrum coverage against various bacterial pathogens.","oneSentence":"This is a combination of two antibiotics: amoxicillin inhibits bacterial cell wall synthesis, while rifabutin inhibits bacterial RNA polymerase to suppress protein synthesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T05:54:31.538Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections susceptible to both amoxicillin and rifabutin (specific indications not clearly defined in available literature)"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05874544","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-16","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT06731023","phase":"","title":"Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Xiuli Zuo","startDate":"2025-01-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":30},{"nctId":"NCT06687473","phase":"PHASE4","title":"Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-01-01","conditions":"Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor","enrollment":13},{"nctId":"NCT06687499","phase":"PHASE4","title":"14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-08-22","conditions":"Helicobacter Pylori, Drug Resistance, Multiple","enrollment":46},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT04879992","phase":"NA","title":"Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-05-07","conditions":"Helicobacter Pylori Infection","enrollment":413},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04652284","phase":"PHASE3","title":"Effectiveness of Rifabutin for Treatment of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2021-05-01","conditions":"Helicobacter Infections, Resistance Bacterial, Gastritis H Pylori","enrollment":300},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT03198507","phase":"PHASE3","title":"ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2017-06-18","conditions":"Helicobacter Pylori Infection, Dyspepsia","enrollment":455},{"nctId":"NCT01980095","phase":"PHASE3","title":"ERADICATE Hp - Treating Helicobacter Pylori With RHB-105","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-11","conditions":"Dyspepsia, Helicobacter Pylori Infection","enrollment":119},{"nctId":"NCT04090021","phase":"PHASE4","title":"Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.","status":"UNKNOWN","sponsor":"Konstantopoulio-Patission General Hospital of Nea Ionia","startDate":"2019-09-01","conditions":"Helicobacter Pylori Infection","enrollment":304}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"amoxicillin rifabutin","genericName":"amoxicillin rifabutin","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two antibiotics: amoxicillin inhibits bacterial cell wall synthesis, while rifabutin inhibits bacterial RNA polymerase to suppress protein synthesis. Used for Bacterial infections susceptible to both amoxicillin and rifabutin (specific indications not clearly defined in available literature).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}